Contraception for the HIV-positive woman: A review of interactions between hormonal contraception and antiretroviral therapy

Infectious Diseases in Obstetrics and Gynecology

Volumn 2012, Issue , 2012, Pages

  Robinson, Jennifer A ^a   Jamshidi, Roxanne ^a   Burke, Anne E ^a  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; COBICISTAT; DESOGESTREL PLUS ETHINYLESTRADIOL; DROSPIRENONE PLUS ETHINYLESTRADIOL; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; ETHINYLESTRADIOL PLUS ETYNODIOL DIACETATE; ETHINYLESTRADIOL PLUS GESTODENE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETHINYLESTRADIOL PLUS NORETHISTERONE; ETHINYLESTRADIOL PLUS NORGESTIMATE; ETHINYLESTRADIOL PLUS NORGESTREL; ETONOGESTREL; ETRAVIRINE; LEVONORGESTREL; LOPINAVIR PLUS RITONAVIR; MARAVIROC; MEDROXYPROGESTERONE ACETATE; NELFINAVIR; NEVIRAPINE; PLACEBO; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; TENOFOVIR; TENOFOVIR DISOPROXIL; ANTIRETROVIRUS AGENT; ORAL CONTRACEPTIVE AGENT;

AREA UNDER THE CURVE; CONTRACEPTIVE DEVICE; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; EMERGENCY CONTRACEPTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; MEDLINE; ORAL CONTRACEPTION; PEER REVIEW; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; VAGINA RING; CONTRACEPTION; DISEASE TRANSMISSION; DRUG INTERACTION; FEMALE; METHODOLOGY; PREGNANCY; VERTICAL TRANSMISSION;

ANTI-RETROVIRAL AGENTS; CONTRACEPTION; CONTRACEPTIVES, ORAL, HORMONAL; DRUG INTERACTIONS; FEMALE; HIV SEROPOSITIVITY; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY;

EID: 84866153559     PISSN: 10647449     EISSN: 10980997     Source Type: Journal    
DOI: 10.1155/2012/890160     Document Type: Review

References (61)

1. UNAIDS/WHO, AIDS Epidemic Update. 2009
2. Reynolds H. W., Janowitz B., Homan R., Johnson L., The value of contraception to prevent perinatal HIV transmission. Sexually Transmitted Diseases 2006 33 6 350 356 2-s2.0-33744821883 10.1097/01.olq.0000194602.01058.e1 (Pubitemid 43833021)
3. Zieman M., Hatcher R. A., Cwiak C., Darney P. D., Creinin M. D., Stosur H. R., A Pocket Guide to Managing Contraception 2007 Tiger, Ga, USA Bridging the Gap Foundation
4. FFPHRC Guidance, Drug interactions with hormonal contraception. Journal of Family Planning and Reproductive Health Care 2005 31 2 139 150
5. Van Den Heuvel M. W., Van Bragt A. J. M., Alnabawy A. K. M., Kaptein M. C. J., Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: The vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005 72 3 168 174 2-s2.0-23644446491 10.1016/j.contraception.2005.03.005 (Pubitemid 41133355)
6. Mahesh V. B., The dynamic interaction between steroids and gonadotropins in the mammalian ovulatory cycle. Neuroscience and Biobehavioral Reviews 1985 9 2 245 260 2-s2.0-0021794420 10.1016/0149-7634(85)90049-1 (Pubitemid 15079231)
7. Hemrika D. J., Slaats E. H., Kennedy J. C., De Vries Robles-Korsen T. J. M., Schoemaker J., Pulsatile luteinizing hormone secretion during the first and the fourth cycle on two different oral contraceptives containing gestodene. Acta Endocrinologica 1993 129 3 229 236 2-s2.0-0027436541 (Pubitemid 23295685)
8. Speroff L., Fritz M., Clinical Gynecologic Endocrinology and Infertility 2005 7th Baltimore, Md, USA Lippincott Williams & Wilkins
9. Guengerich F. P., Metabolism of 17 α -ethynylestradiol in humans. Life Sciences 1990 47 22 1981 1988 2-s2.0-0025688510 10.1016/0024-3205(90)90431- P
10. Edelman A. B., Cherala G., Stanczyk F. Z., Metabolism and pharmacokinetics of contraceptive steroids in obese women: a review. Contraception 2010 82 4 314 323 2-s2.0-77956910985 10.1016/j.contraception.2010. 04.016
11. Panel on Antiretroviral Guidelines for Adults and Adolescents, Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, 2009
12. Bristol-Meyers Squibb, Reyataz (atazanavir) Package Label, 2010
13. Agouron Pharmaceuticals, Viracept (nelfinavir) Package Label, 2009
14. Abbott Laboratories, Kaletra (lopinavir/ritonavir) Package Label, 2010
15. Vogler M. A., Patterson K., Kamemoto L., Park J. G., Watts H., Aweeka F., Klingman K. L., Cohn S. E., Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: Pharmacokinetic results of ACTG trial A5188. Journal of Acquired Immune Deficiency Syndromes 2010 55 4 473 482 2-s2.0-78650788111 10.1097/QAI. 0b013e3181eb5ff5
16. Ouellet D., Hsu A., Qian J., Locke C. S., Eason C. J., Cavanaugh J. H., Leonard J. M., Granneman G. R., Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. British Journal of Clinical Pharmacology 1998 46 2 111 116 2-s2.0-0031857385 10.1046/j.1365-2125.1998.00749. x (Pubitemid 28342780)
17. Boehringer Ingelheim Pharmaceuticals, Viramune (nevirapine) Package Label, 2010
18. Mildvan D., Yarrish R., Marshak A., Hutman H. W., McDonough M., Lamson M., Robinson P., Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women. Journal of Acquired Immune Deficiency Syndromes 2002 29 5 471 477 2-s2.0-0036238929 (Pubitemid 34456338)
19. Bristol-Meyers Squibb, Sustiva (efavirenz) Package Label, 2010
20. Sevinsky H., Eley T., Persson A., Garner D., Yones C., Nettles R., Krantz K., Bertz R., Zhang J., The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women. Antiviral Therapy 2011 16 2 149 156 2-s2.0-79953192509 10.3851/IMP1725
21. Janssen Pharmaceuticals, Intelence (etravirine) Package Label, 2008
22. Schöller-Gyüre M., Kakuda T. N., Woodfall B., Aharchi F., Peeters M., Vandermeulen K., Hoetelmans R. M. W., Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone. Contraception 2009 80 1 44 52 2-s2.0-66549114704 10.1016/j.contraception.2009.01.009
23. Anderson M. S., Hanley W. D., Moreau A. R., Jin B., Bieberdorf F. A., Kost J. T., Wenning L. A., Stone J. A., Wagner J. A., Iwamoto M., Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women. British Journal of Clinical Pharmacology 2011 71 4 616 620 2-s2.0-79952615562 10.1111/j.1365-2125.2010. 03885.x
24. German P., Wang M., Warren D., Kearney B. P., Pharmacokinetic interaction between Norgestimate/Ethinyl Estradiol and EVG/COBI/FTC/TDF single tablet regimen. Proceedings of the 12th International Workshop on Clinical Pharmacology of HIV Therapy April 2011 Miami, Fla, USA
25. Cohn S. E., Park J. G., Watts D. H., Stek A., Hitti J., Clax P. A., Yu S., Lertora J. J. L., Depo-medroxyprogesterone in women on antiretroviral therapy: Effective contraception and lack of clinically significant interactions. Clinical Pharmacology and Therapeutics 2007 81 2 222 227 2-s2.0-33846592800 10.1038/sj.clpt.6100040 (Pubitemid 46174819)
26. Nanda K., Amaral E., Hays M., Viscola M. A. M., Mehta N., Bahamondes L., Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy. Fertility and Sterility 2008 90 4 965 971 2-s2.0-52949087968 10.1016/j.fertnstert.2007.07.1348
27. Matiluko A. A., Soundararjan L., Hogston P., Early contraceptive failure of Implanon in an HIV-seropositive patient on triple antiretroviral therapy with zidovudine, lamivudine and efavirenz. Journal of Family Planning and Reproductive Health Care 2007 33 4 277 278 2-s2.0-35348968894 (Pubitemid 47597636)
28. Lakhi N., Govind A., Implanon failure in patients on antiretroviral medication: the importance of disclosure. Journal of Family Planning and Reproductive Health Care 2010 36 3 181 182 2-s2.0-77954848144
29. McCarty E. J., Keane H., Quinn K., Quah S., Implanonw failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies. International Journal of STD and AIDS 2011 22 7 413 414 2-s2.0-79960172746 10.1258/ijsa.2009.009469
30. Leticee N., Viard J.-P., Yamgnane A., Karmochkine M., Benachi A., Contraceptive failure of etonogestrel implant in patients treated with antiretrovirals including efavirenz. Contraception 2012 85 4 425 427 10.1016/j.contraception.2011.09.005
31. Heikinheimo O., Lehtovirta P., Suni J., Paavonen J., The levonorgestrel-releasing intrauterine system (LNG-IUS) in HIV-infected womeneffects on bleeding patterns, ovarian function and genital shedding of HIV. Human Reproduction 2006 21 11 2857 2861 2-s2.0-33750012689 10.1093/humrep/ del264 (Pubitemid 44566998)
32. Lehtovirta P., Paavonen J., Heikinheimo O., Experience with the levonorgestrel-releasing intrauterine system among HIV-infected women. Contraception 2007 75 1 37 39 2-s2.0-33845191338 10.1016/j.contraception.2006. 09.006 (Pubitemid 44854865)
33. Heikinheimo O., Lehtovirta P., Aho I., Ristola M., Paavonen J., The levonorgestrel-releasing intrauterine system in human immunodeficiency virusinfected women: Z 5-year follow-up study. American Journal of Obstetrics and Gynecology 2011 204 2 126.e1 126.e4 2-s2.0-79551474311 10.1016/j.ajog.2010. 09.002
34. Carten M. L., Kiser J., Kwara A., MaWhinney S., Cu-Uvin S., Pharmacokinetic (PK) interactions between the hormonal emergency contraception Plan B (levonorgestrel) and efavirenz (EFV). Proceedings of the 17th Conference on Retroviruses and Opportunistic Infections February 2010 San Francisco, Calif, USA
35. Department of Health and Human Services Centers for Disease Control and Prevention, US medical eligibility criteria for contraceptive use. Morbidity and Mortality Weekly Report 2010 59 4 1 86 2-s2.0-77953987129
36. Wyeth Laboratories. LoOvral (ethinyl estradiol/norgestrel) Package label, 2007
37. Wyeth Pharmaceuticals, Alesse (ethinyl estradiol/levonorgestrel) Package Label, 2008
38. Ortho-McNeil-Janssen Pharmaceuticals, Ortho TriCyclen (ethinyl estradiol/norgestimate) Package Label, 2009
39. Bayer HealthCare Pharmaceuticals, Yaz (ethinyl estradiol/drospirenone) Package Label, 2010
40. Duramed, Mircette (ethinyl estradiol/desogestrel) Package Label, 2009
41. GlaxoSmithKline, Agenerase (amprenavir) Package Label, 2002
42. Abbott Laboratories, Norvir (ritonavir) Package Label, 2010
43. Janssen Therapeuics, Prezista (darunavir) Package Label, 2008
44. Boehringer Ingelheim Pharmaceuticals, Aptivus (tipranavir) Package Label, 2011
45. Roche Laboratories, Invirase/Fortovase (saquinavir) Package Label, 2010
46. Fröhlich M., Burhenne J., Martin-Facklam M., Weiss J., Von Wolff M., Strowitzki T., Walter-Sack I., Haefeli W. E., Oral contraception does not alter single dose saquinavir pharmacokinetics in women. British Journal of Clinical Pharmacology 2004 57 3 244 252 2-s2.0-1542299795 10.1111/j.1365-2125.2003.01983. x (Pubitemid 38296987)
47. Abel S., Russell D., Whitlock L. A., Ridgway C. E., Muirhead G. J., Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers. British Journal of Clinical Pharmacology 2008 65 1 19 26 2-s2.0-40549090550 10.1111/j.1365-2125. 2008.03132.x (Pubitemid 351366535)
48. Merck and Company, Isentress (raltegravir) Package Label, 2011
49. Organon, NuvaRing Package Label, 2010
50. Janssen-Ortho, Micronor (norethindrone) Package Label, 2010
51. Pfizer, Depo-Provera (depot medroxyprogesterone acetate) Package Label, 2006
52. Watts D. H., Park J. G., Cohn S. E., Yu S., Hitti J., Stek A., Clax P. A., Muderspach L., Lertora J. J. L., Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093. Contraception 2008 77 2 84 90 2-s2.0-38349121002 10.1016/j.contraception.2007.10.002
53. Bayer HealthCare Pharmaceuticals, Mirena (levonorgestrel-releasing intrauterine system) Package Label, 2009
54. Barr Pharmaceuticals, Plan B (levonorgestrel emergency contraceptive tablet) Product Labeling, 2006
55. Trussell J., Raymond E. G., Emergency Contraception: a last chance to prevent unintended pregnancy. 2012
56. Stewart F. H., Trussell J., Van Look P. F. A., Hatcher R. A., Trussell J., Nelson A. L., Cates W. Jr., Stewart F. H., Kowal D., Chapter 6: emergency contraception. Contraceptive Technology 2008 19th New York, NY, USA Ardent Media 87 116
57. Juday T., Gupta S., Grimm K., Wagner S., Kim E., Factors associated with complete adherence to HIV combination antiretroviral therapy. HIV Clinical Trials 2011 12 2 71 78 2-s2.0-79955063837 10.1310/hct1202-71
58. Atkinson M. J., Petrozzino J. J., An evidence-based review of treatment-related determinants of patients' nonadherence to HIV medications. AIDS Patient Care and STDs 2009 23 11 903 914 2-s2.0-72849149158 10.1089/apc.2009.0024
59. World Health Organization, Department of Reproductive Health and Research, Hormonal contraception and HIV. Technical statement 2012 Geneva, Switzerland
60. Heffron R., Donnell D., Rees H., Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. The Lancet Infectious Diseases 2012 12 1 19 26
61. World Health Organization, Medical Eligibility Criteria for Contraceptive Use 2010 Geneva, Switzerland World Health Organization